| 1 | receive | 23,516 |
| 2 | self-administer | 37 |
| 3 | reintroduce | 8 |
| 4 | self-collect | 8 |
| 5 | add-on-statin | 4 |
| 6 | meditate | 4 |
| 7 | up-titrate | 3 |
| 8 | smoke/ws | 2 |
| 9 | ≥6/12 | 2 |
| 10 | 'nurse-led | 1 |
| 11 | -1.80+/-0.4 | 1 |
| 12 | 0-100mg/l | 1 |
| 13 | 0.26μg/kg | 1 |
| 14 | 0.3/ | 1 |
| 15 | 0.46μg/kg | 1 |
| 16 | 0.95-cm | 1 |
| 17 | 0/62 | 1 |
| 18 | 05.2014. | 1 |
| 19 | 1-methyl-1,2,3,6-tetrahydropiridine-induced | 1 |
| 20 | 12.5/7.5mg | 1 |
| 21 | 13220 | 1 |
| 22 | 3.7μmol | 1 |
| 23 | 31/01/2011 | 1 |
| 24 | 342.2±56 | 1 |
| 25 | 349+/-96 | 1 |
| 26 | 381.3±39 | 1 |
| 27 | 497+/-28 | 1 |
| 28 | 540-mg | 1 |
| 29 | 6-amino | 1 |
| 30 | 6.1mm | 1 |
| 31 | 7-day-a-week | 1 |
| 32 | 72,028 | 1 |
| 33 | 750-g-bw | 1 |
| 34 | 960-mg | 1 |
| 35 | acrylated | 1 |
| 36 | adozelesin | 1 |
| 37 | alkylating-containing | 1 |
| 38 | anti-mtor-based | 1 |
| 39 | barley-soybean | 1 |
| 40 | biosynthesise | 1 |
| 41 | bisindoles | 1 |
| 42 | co-develop | 1 |
| 43 | coccidioidin | 1 |
| 44 | community-prescribed | 1 |
| 45 | control-referenced | 1 |
| 46 | cystoscape | 1 |
| 47 | dalcetrapib-matched | 1 |
| 48 | dereplicate | 1 |
| 49 | dietitian-entered | 1 |
| 50 | diuretics/ | 1 |
| 51 | effective.a | 1 |
| 52 | entero-soluble | 1 |
| 53 | euthanize | 1 |
| 54 | f400 | 1 |
| 55 | gcs-nonexposed | 1 |
| 56 | gender-to | 1 |
| 57 | hepta-chlorinated | 1 |
| 58 | high-osmolal | 1 |
| 59 | high.a | 1 |
| 60 | hydrochloride/caffeine/8-chlorotheophylline | 1 |
| 61 | ifnα-based | 1 |
| 62 | in-residence | 1 |
| 63 | indude | 1 |
| 64 | isonitrogeneous | 1 |
| 65 | kasugai | 1 |
| 66 | la-free | 1 |
| 67 | ldlx-treated | 1 |
| 68 | liquid-nitrogen | 1 |
| 69 | loperamide-encapsulated | 1 |
| 70 | lrt+ | 1 |
| 71 | lrtp | 1 |
| 72 | mcao-r. | 1 |
| 73 | medium-containing | 1 |
| 74 | moderated-intensity | 1 |
| 75 | n-g-monomethyl | 1 |
| 76 | nasal-spray-administered | 1 |
| 77 | ndv-induced | 1 |
| 78 | neadjuvant | 1 |
| 79 | no/delayed | 1 |
| 80 | nonaccurate | 1 |
| 81 | oust | 1 |
| 82 | over-call | 1 |
| 83 | overweight- | 1 |
| 84 | photodegrade | 1 |
| 85 | placebo.after | 1 |
| 86 | porphyrin-mediated | 1 |
| 87 | post-storage | 1 |
| 88 | prefilling | 1 |
| 89 | rabbit-derived | 1 |
| 90 | ral-containing | 1 |
| 91 | re-approve | 1 |
| 92 | re-license | 1 |
| 93 | reduced-port | 1 |
| 94 | sandblast-treated | 1 |
| 95 | self-discrepant | 1 |
| 96 | sfc50/ | 1 |
| 97 | shabiehkhani | 1 |
| 98 | sitaglipin | 1 |
| 99 | solvent-bound | 1 |
| 100 | tolerate≥1 | 1 |
| 101 | treastment | 1 |
| 102 | type-i-ifn-based | 1 |
| 103 | uv/commercial | 1 |
| 104 | verum/placebo | 1 |
| 105 | withdrawal.for | 1 |
| 106 | written/verbal | 1 |
| 107 | zdv/lamivudine/ritonavir-boosted | 1 |
| 1 | 'nurse-led | 1 |
| 2 | -1.80+/-0.4 | 1 |
| 3 | 0-100mg/l | 1 |
| 4 | 0.26μg/kg | 1 |
| 5 | 0.3/ | 1 |
| 6 | 0.46μg/kg | 1 |
| 7 | 0.95-cm | 1 |
| 8 | 0/62 | 1 |
| 9 | 05.2014. | 1 |
| 10 | 1-methyl-1,2,3,6-tetrahydropiridine-induced | 1 |
| 11 | 12.5/7.5mg | 1 |
| 12 | 13220 | 1 |
| 13 | 3.7μmol | 1 |
| 14 | 31/01/2011 | 1 |
| 15 | 342.2±56 | 1 |
| 16 | 349+/-96 | 1 |
| 17 | 381.3±39 | 1 |
| 18 | 497+/-28 | 1 |
| 19 | 540-mg | 1 |
| 20 | 6-amino | 1 |
| 21 | 6.1mm | 1 |
| 22 | 7-day-a-week | 1 |
| 23 | 72,028 | 1 |
| 24 | 750-g-bw | 1 |
| 25 | 960-mg | 1 |
| 26 | acrylated | 1 |
| 27 | add-on-statin | 4 |
| 28 | adozelesin | 1 |
| 29 | alkylating-containing | 1 |
| 30 | anti-mtor-based | 1 |
| 31 | barley-soybean | 1 |
| 32 | biosynthesise | 1 |
| 33 | bisindoles | 1 |
| 34 | co-develop | 1 |
| 35 | coccidioidin | 1 |
| 36 | community-prescribed | 1 |
| 37 | control-referenced | 1 |
| 38 | cystoscape | 1 |
| 39 | dalcetrapib-matched | 1 |
| 40 | dereplicate | 1 |
| 41 | dietitian-entered | 1 |
| 42 | diuretics/ | 1 |
| 43 | effective.a | 1 |
| 44 | entero-soluble | 1 |
| 45 | euthanize | 1 |
| 46 | f400 | 1 |
| 47 | gcs-nonexposed | 1 |
| 48 | gender-to | 1 |
| 49 | hepta-chlorinated | 1 |
| 50 | high-osmolal | 1 |
| 51 | high.a | 1 |
| 52 | hydrochloride/caffeine/8-chlorotheophylline | 1 |
| 53 | ifnα-based | 1 |
| 54 | in-residence | 1 |
| 55 | indude | 1 |
| 56 | isonitrogeneous | 1 |
| 57 | kasugai | 1 |
| 58 | la-free | 1 |
| 59 | ldlx-treated | 1 |
| 60 | liquid-nitrogen | 1 |
| 61 | loperamide-encapsulated | 1 |
| 62 | lrt+ | 1 |
| 63 | lrtp | 1 |
| 64 | mcao-r. | 1 |
| 65 | meditate | 4 |
| 66 | medium-containing | 1 |
| 67 | moderated-intensity | 1 |
| 68 | n-g-monomethyl | 1 |
| 69 | nasal-spray-administered | 1 |
| 70 | ndv-induced | 1 |
| 71 | neadjuvant | 1 |
| 72 | no/delayed | 1 |
| 73 | nonaccurate | 1 |
| 74 | oust | 1 |
| 75 | over-call | 1 |
| 76 | overweight- | 1 |
| 77 | photodegrade | 1 |
| 78 | placebo.after | 1 |
| 79 | porphyrin-mediated | 1 |
| 80 | post-storage | 1 |
| 81 | prefilling | 1 |
| 82 | rabbit-derived | 1 |
| 83 | ral-containing | 1 |
| 84 | re-approve | 1 |
| 85 | re-license | 1 |
| 86 | receive | 23,516 |
| 87 | reduced-port | 1 |
| 88 | reintroduce | 8 |
| 89 | sandblast-treated | 1 |
| 90 | self-administer | 37 |
| 91 | self-collect | 8 |
| 92 | self-discrepant | 1 |
| 93 | sfc50/ | 1 |
| 94 | shabiehkhani | 1 |
| 95 | sitaglipin | 1 |
| 96 | smoke/ws | 2 |
| 97 | solvent-bound | 1 |
| 98 | tolerate≥1 | 1 |
| 99 | treastment | 1 |
| 100 | type-i-ifn-based | 1 |
| 101 | up-titrate | 3 |
| 102 | uv/commercial | 1 |
| 103 | verum/placebo | 1 |
| 104 | withdrawal.for | 1 |
| 105 | written/verbal | 1 |
| 106 | zdv/lamivudine/ritonavir-boosted | 1 |
| 107 | ≥6/12 | 2 |
| 1 | lrt+ | 1 |
| 2 | overweight- | 1 |
| 3 | 05.2014. | 1 |
| 4 | mcao-r. | 1 |
| 5 | sfc50/ | 1 |
| 6 | 0.3/ | 1 |
| 7 | diuretics/ | 1 |
| 8 | f400 | 1 |
| 9 | 13220 | 1 |
| 10 | 31/01/2011 | 1 |
| 11 | tolerate≥1 | 1 |
| 12 | ≥6/12 | 2 |
| 13 | 0/62 | 1 |
| 14 | -1.80+/-0.4 | 1 |
| 15 | 342.2±56 | 1 |
| 16 | 349+/-96 | 1 |
| 17 | 497+/-28 | 1 |
| 18 | 72,028 | 1 |
| 19 | 381.3±39 | 1 |
| 20 | effective.a | 1 |
| 21 | high.a | 1 |
| 22 | community-prescribed | 1 |
| 23 | control-referenced | 1 |
| 24 | 1-methyl-1,2,3,6-tetrahydropiridine-induced | 1 |
| 25 | ndv-induced | 1 |
| 26 | dalcetrapib-matched | 1 |
| 27 | 'nurse-led | 1 |
| 28 | dietitian-entered | 1 |
| 29 | nasal-spray-administered | 1 |
| 30 | type-i-ifn-based | 1 |
| 31 | anti-mtor-based | 1 |
| 32 | ifnα-based | 1 |
| 33 | gcs-nonexposed | 1 |
| 34 | sandblast-treated | 1 |
| 35 | ldlx-treated | 1 |
| 36 | porphyrin-mediated | 1 |
| 37 | loperamide-encapsulated | 1 |
| 38 | acrylated | 1 |
| 39 | hepta-chlorinated | 1 |
| 40 | zdv/lamivudine/ritonavir-boosted | 1 |
| 41 | rabbit-derived | 1 |
| 42 | no/delayed | 1 |
| 43 | solvent-bound | 1 |
| 44 | in-residence | 1 |
| 45 | reintroduce | 8 |
| 46 | photodegrade | 1 |
| 47 | indude | 1 |
| 48 | la-free | 1 |
| 49 | post-storage | 1 |
| 50 | entero-soluble | 1 |
| 51 | hydrochloride/caffeine/8-chlorotheophylline | 1 |
| 52 | cystoscape | 1 |
| 53 | biosynthesise | 1 |
| 54 | re-license | 1 |
| 55 | dereplicate | 1 |
| 56 | up-titrate | 3 |
| 57 | nonaccurate | 1 |
| 58 | meditate | 4 |
| 59 | receive | 23,516 |
| 60 | re-approve | 1 |
| 61 | euthanize | 1 |
| 62 | 0.26μg/kg | 1 |
| 63 | 0.46μg/kg | 1 |
| 64 | 540-mg | 1 |
| 65 | 960-mg | 1 |
| 66 | 12.5/7.5mg | 1 |
| 67 | prefilling | 1 |
| 68 | alkylating-containing | 1 |
| 69 | ral-containing | 1 |
| 70 | medium-containing | 1 |
| 71 | kasugai | 1 |
| 72 | shabiehkhani | 1 |
| 73 | 7-day-a-week | 1 |
| 74 | 0-100mg/l | 1 |
| 75 | written/verbal | 1 |
| 76 | uv/commercial | 1 |
| 77 | high-osmolal | 1 |
| 78 | over-call | 1 |
| 79 | 3.7μmol | 1 |
| 80 | n-g-monomethyl | 1 |
| 81 | 0.95-cm | 1 |
| 82 | 6.1mm | 1 |
| 83 | barley-soybean | 1 |
| 84 | liquid-nitrogen | 1 |
| 85 | coccidioidin | 1 |
| 86 | sitaglipin | 1 |
| 87 | adozelesin | 1 |
| 88 | add-on-statin | 4 |
| 89 | verum/placebo | 1 |
| 90 | 6-amino | 1 |
| 91 | gender-to | 1 |
| 92 | co-develop | 1 |
| 93 | lrtp | 1 |
| 94 | placebo.after | 1 |
| 95 | self-administer | 37 |
| 96 | withdrawal.for | 1 |
| 97 | bisindoles | 1 |
| 98 | isonitrogeneous | 1 |
| 99 | smoke/ws | 2 |
| 100 | self-collect | 8 |
| 101 | self-discrepant | 1 |
| 102 | neadjuvant | 1 |
| 103 | treastment | 1 |
| 104 | reduced-port | 1 |
| 105 | oust | 1 |
| 106 | 750-g-bw | 1 |
| 107 | moderated-intensity | 1 |